A new black box warning has been added to the labeling of all interferon alfa products (Intron A, Rebetron, Roferon-A).
Part D Plans Cover a Larger Share of Medicare Beneficiaries in Rural Counties
Nationwide, 58% of Medicare beneficiaries living in rural areas are enrolled in stand-alone prescription drug plans in 2025.
Read More
FDA Issues CRL for Extended Dosing of Eylea HD
The complete response letter did not identify any issues with the safety or efficacy of Eylea HD, Regeneron officials said.
FDA Approves Dupixent for Inflammatory Skin Disease
Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden and debilitating hives and recurring itch.
FDA Sets Action Date for Eylea HD in Retinal Vein Occlusion
If approved, Eylea would be the first treatment for RVO with 8-week dosing. The FDA target action date is Aug. 19, 2025.
Novo Nordisk Warns about More Counterfeit Ozempic
The FDA has seized several hundred units of counterfeit Ozempic 1 mg
Liver Injury Ends Development of Pfizer’s Oral GLP-1 for Obesity
In one study, once-daily danuglipron resulted in one patient who experienced drug-related elevated liver enzymes.